Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of ALLN-346

Trial Profile

A clinical trial of ALLN-346

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs ALLN 346 (Primary)
  • Indications Hyperuricaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Nov 2018 New trial record
    • 07 Nov 2018 According to an Allena Pharmaceuticals media release, the company expects to file an IND application with the FDA in 2019 and initiation of this trial is expected in the first half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top